Tsuchiura Kyodo General Hospital
Welcome,         Profile    Billing    Logout  
 0 Trials 
16 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Canani, Luis Henrique S
DREAM-T2D, NCT04854512 / 2020-000763-23: Investigational Study of Delayed Release Metformin

Suspended
3
675
Europe, Canada, US, RoW
Metformin DR, ANJ900, MetDR, Metformin IR, Metformin DR Placebo, Metformin IR placebo
Anji Pharma
Diabetes Mellitus, Type 2
12/23
06/24
SURMOUNT-OSA, NCT05412004: Obstructive Sleep Apnea Master Protocol GPIF: A Study of Tirzepatide (LY3298176) in Participants With Obstructive Sleep Apnea

Completed
3
469
Europe, Japan, US, RoW
Tirzepatide, LY3298176, Placebo
Eli Lilly and Company
Sleep Apnea, Obesity
03/24
03/24
NCT06292013: A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)

Recruiting
3
12500
Europe, Canada, Japan, US, RoW
Lepodisiran Sodium, LY3819469, Placebo
Eli Lilly and Company
Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a)
03/29
03/29
NCT06383390: The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)

Recruiting
3
10000
Europe, Canada, US, RoW
Retatrutide, LY3437943, Placebo
Eli Lilly and Company
Atherosclerotic Cardiovascular Disease (ASCVD), Chronic Kidney Disease (CKD)
02/29
02/29
ATTAIN-OSA, NCT06649045: A Master Protocol for Orforglipron in Participants With Obstructive Sleep Apnea and Obesity or Overweight

Recruiting
3
600
Europe, Japan, US, RoW
Orforglipron, LY3502970, Placebo
Eli Lilly and Company
OSA, Overweight or Obesity
11/26
01/27
ACHIEVE-4, NCT05803421: A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk

Active, not recruiting
3
2749
Europe, US, RoW
Orforglipron, LY3502970, Insulin Glargine
Eli Lilly and Company
Type 2 Diabetes, Obesity, Overweight or Obesity, Overweight, Cardiovascular Diseases, Chronic Kidney Disease
09/25
01/26
ATTAIN-1, NCT05869903: A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities

Active, not recruiting
3
3000
Europe, Japan, US, RoW
Orforglipron, LY3502970, Placebo
Eli Lilly and Company
Obesity, Overweight, Overweight or Obesity
07/25
07/27
SURMOUNT-MMO, NCT05556512: A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity

Active, not recruiting
3
15374
Europe, Canada, Japan, US, RoW
Tirzepatide, LY3298176, Placebo
Eli Lilly and Company
Obesity, Overweight
10/27
10/27
Kakuta, Tsunekazu
NCT06292013: A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)

Recruiting
3
12500
Europe, Canada, Japan, US, RoW
Lepodisiran Sodium, LY3819469, Placebo
Eli Lilly and Company
Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a)
03/29
03/29
EMPA-AHF, NCT05392764: Early Treatment With a Sodium-glucose Co-transporter 2 Inhibitor in High-risk Patients With Acute Heart Failure

Recruiting
3
524
Japan
Empagliflozin 10 MG, Placebo
Juntendo University, Boehringer Ingelheim
Acute Heart Failure
03/25
12/27
NCT04840914: A Study of LY3461767 in Participants With Chronic Heart Failure With Reduced Ejection Fraction

Completed
1
44
Japan, US
LY3461767, Placebo
Eli Lilly and Company
Chronic Heart Failure With Reduced Ejection Fraction
05/24
05/24
POST-PCI FLOW, NCT04684043: Prognostic Implications of Physiologic Investigation After Revascularization With Stent

Recruiting
N/A
5100
RoW
Percutaneous coronary intervention
Bon-Kwon Koo, Inje University Ilsan Paik Hospital, Goyang, South Korea, Nanjing First Hospital, Nanjing Medical University, Nanjing, China, Tsuchiura Kyodo General Hospital, Ibaraki, Japan, McGovern Medical School at UTHealth and Memorial Hermann Hospital, TX, USA, Nagoya City University Graduate School of Medical Science, Nagoya, Japan, Rutgers Robert Wood Johnson Medical School, New Brunswick, New Jersey, Cardiovascular Center Aalst, OLV Clinic, Aalst, Belgium, San Raffaele Scientific Institute, Milan, Italy, Ajou University Hospital, Suwon, South Korea, University of Cincinnati, Cincinnati, OH, USA, Kyoto Second Red Cross Hospital, Kyoto, Japan, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea, Tokyo Medical University Hachioji Medical Center, Tokyo, Japan
Coronary Disease
02/21
02/21
JDEPTH-LM, NCT06436092: Japanese Coronary Intervention Using Drug Eluting and Perfusion Therapy for Left Main Disease ( Registry)

Recruiting
N/A
280
Japan
TCROSS Co., Ltd., Kaneka Corporation
Stable Angina, Non-ST-elevation Acute Coronary Syndrome, Unstable Angina
05/27
12/29
NCT04523194: Massachusetts General Hospital and Tsuchiura Kyodo General Hospital Coronary Imaging Collaboration

Recruiting
N/A
1000
Japan, US
Optical Coherence Tomography (OCT) and Computed Tomography Angiography (CTA)
Massachusetts General Hospital, Tsuchiura Kyodo General Hospital
Atherosclerosis
12/25
12/25
Osanai, Takayuki
EMBER-3, NCT04975308 / 2021-000079-35: A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer

Active, not recruiting
3
866
Europe, Japan, US, RoW
Imlunestrant, LY3484356, Exemestane, Fulvestrant, Abemaciclib, LY2835219
Eli Lilly and Company, Eli Lilly and Company
Breast Neoplasms, Neoplasm Metastasis
06/24
08/27
Nakagawa, Tsuyoshi
EMBER-3, NCT04975308 / 2021-000079-35: A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer

Active, not recruiting
3
866
Europe, Japan, US, RoW
Imlunestrant, LY3484356, Exemestane, Fulvestrant, Abemaciclib, LY2835219
Eli Lilly and Company, Eli Lilly and Company
Breast Neoplasms, Neoplasm Metastasis
06/24
08/27

Download Options